CN117279639A - 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 - Google Patents

使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 Download PDF

Info

Publication number
CN117279639A
CN117279639A CN202180097818.8A CN202180097818A CN117279639A CN 117279639 A CN117279639 A CN 117279639A CN 202180097818 A CN202180097818 A CN 202180097818A CN 117279639 A CN117279639 A CN 117279639A
Authority
CN
China
Prior art keywords
compound
cancer
therapeutically effective
effective dose
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180097818.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·T·格雷威
U·菲利帕
T·C·王尔德
M·E·威廉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN117279639A publication Critical patent/CN117279639A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180097818.8A 2021-03-03 2021-03-03 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法 Pending CN117279639A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2021/051776 WO2022185097A1 (en) 2021-03-03 2021-03-03 Method of treating a condition using a therapeutically effective dose of the malt1 inhibitor jnj -67856633 (1 -(1 -oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1 h-py razole-4-carboxamide)

Publications (1)

Publication Number Publication Date
CN117279639A true CN117279639A (zh) 2023-12-22

Family

ID=74860360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180097818.8A Pending CN117279639A (zh) 2021-03-03 2021-03-03 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法

Country Status (10)

Country Link
US (1) US20240299376A1 (https=)
EP (1) EP4301364A1 (https=)
JP (1) JP2024508890A (https=)
KR (1) KR20230154227A (https=)
CN (1) CN117279639A (https=)
AU (1) AU2021431485A1 (https=)
BR (1) BR112023017689A2 (https=)
CA (1) CA3212339A1 (https=)
MX (1) MX2023010322A (https=)
WO (1) WO2022185097A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
CN118451068A (zh) * 2021-12-30 2024-08-06 上海翰森生物医药科技有限公司 三并环类衍生物抑制剂、其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12269813B2 (en) 2019-02-22 2025-04-08 Janssen Pharmaceutica Nv Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate
US20220175760A1 (en) * 2019-02-22 2022-06-09 Janssen Pharmaceutica Nv Pharmaceutical formulations

Also Published As

Publication number Publication date
EP4301364A1 (en) 2024-01-10
WO2022185097A1 (en) 2022-09-09
JP2024508890A (ja) 2024-02-28
AU2021431485A1 (en) 2023-10-19
MX2023010322A (es) 2023-11-24
BR112023017689A2 (pt) 2023-11-14
US20240299376A1 (en) 2024-09-12
KR20230154227A (ko) 2023-11-07
CA3212339A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
US9107926B2 (en) Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
TWI719960B (zh) 新穎組成物
TW202400153A (zh) Ｋｒａｓｇ１２ｃ抑制劑之治療用途
JP7668777B2 (ja) 癌治療
EA039392B1 (ru) Способ лечения рака с применением замещенного аминопуринового соединения
CN105848682A (zh) 药物组合
CN117279639A (zh) 使用治疗有效剂量的malt1抑制剂jnj-67856633（1-(1-氧代-1,2-二氢异喹啉-5-基)-5-(三氟甲基)-n-(2-(三氟甲基)吡啶-4-基)-1h-吡唑-4-甲酰胺）治疗病状的方法
TW201526894A (zh) 藉二氫吡并吡治療癌症
KR102444494B1 (ko) 비정상적 세포 성장의 치료를 위한 조성물 및 방법
WO2022261643A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
KR20120099219A (ko) 조합물
JP5890310B2 (ja) 組合せ
CN114340625B (zh) 用雌激素受体-α抑制剂的口服剂型治疗癌症的方法
CN115529816A (zh) 使用(R)-N-(3-氟-4-((3-((1-羟基丙-2-基)氨基)-1H-吡唑并[3,4-b]吡啶-4-基)氧基)苯基)-3-(4-氟苯基)-1-异丙基-2,4-二氧-1,2,3,4-四氢嘧啶-5-甲酰胺治疗癌症的方法
RU2844940C2 (ru) Способ лечения рака с помощью пероральной лекарственной формы ингибитора рецептора эстрогена альфа
US20230090742A1 (en) Aminopyrimidinylaminobenzonitrile derivatives as nek2 inhibitors
CN121729222A (zh) 西达尿苷和阿扎胞苷的固定剂量组合
WO2026064575A1 (en) Methods for treating cancer
JP2023502264A (ja) 固体用量医薬組成物
NZ629860B (en) Methods for treating cancer using tor kinase inhibitor combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination